Forte Biosciences Inc. (FBRX)

In the past six months, Forte Biosciences, Inc. has experienced several events impacting its stock price. The stock had seen a significant increase of over 120% on a six-month basis as of April 10, 2026. Key events include the pricing of a $150 million public offering, announcement of 2025 results, inducement grants under Nasdaq Listing Rules, presentations at investor meetings, missing analyst earnings expectations for Q1 2026 with increased R&D expenses, and positive FB102 data from a Phase 1b study in Celiac disease.

Forte Biosciences, Inc. does not typically experience demand seasonality for its products and services. The demand for its product candidate, FB102, is driven by the ongoing medical need for treatments for conditions like celiac disease, vitiligo, and alopecia areata, rather than seasonal fluctuations.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on advancing its lead product candidate, FB102, a monoclonal antibody for autoimmune and autoimmune-related indications. The company is currently developing FB102 in clinical trials for celiac disease, non-segmental vitiligo, and alopecia areata. The company previously discontinued development of FB-401 for atopic dermatitis after disappointing trial results.

Forte Biosciences, Inc. has its principal executive office in Dallas, Texas, United States. It also has a subsidiary, Forte Biosciences Australia Proprietary Limited. Its shares are traded on The Nasdaq Capital Market under the ticker FBRX, and also on the Deutsche Boerse AG (Frankfurt, Munich, and Stuttgart Stock Exchanges).

In the past year, Forte Biosciences' reputation has faced scrutiny due to a large shareholder publicly criticizing the company's board of directors and discussions questioning the company's business plan. These events suggest some negative sentiment and concerns regarding corporate governance and strategic direction.

Forte Biosciences Inc. is primarily owned by institutional shareholders (91.99%) and Forte Biosciences insiders (49.22%). Retail investors hold a very small percentage (0.00%). Major institutional owners include Federated Hermes, Inc., Fred Alger Management, LLC, Janus Henderson Group Plc, Orbimed Advisors Llc, Affinity Asset Advisors, LLC, Tybourne Capital Management (hk) Ltd, Vanguard Group Inc, Point72 Asset Management, L.P., Cable Car Capital LLC, Adage Capital Partners Gp, L.l.c., BlackRock, Inc., and Millennium Management LLC. The largest individual shareholder is Steven Michael Oliveira, who owns 4.14 million shares, representing 33.04% of the company.